leadf
logo-loader
viewIQ-AI Limited

IQ-AI's David Smith updates on patents and StoneChecker FDA process

David Smith, chief executive of IQ-AI Limited's (LON:IQAI)  operating subsidiaries, spoke to Proactive London's Andrew Scott about the recent filing of a patent for gadolinium-free magnetic resonance imaging (MRI) scan.

Over the past decade, research has shown the potential toxicity of gadolinium-based products and how they are retained in the body for several years.

Smith also talks through how the FDA approval process is coming along for their kidney stone medical imaging software StoneChecker.

Once approved, the group aims to launch the software in the US, India and China by the end of the year while commercial sales in the UK are expected to begin in the fourth quarter.

Quick facts: IQ-AI Limited

Price: 12.8 GBX

LSE:IQAI
Market: LSE
Market Cap: £20.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise...

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before...

on 15/7/20

2 min read